Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 2/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879813 | 1.00 | CYP2C9 (0.46) | CYP2C9CYP2C19HCRTR1HCRTR2UBE2M | |
| SCHEMBL18532595 | 0.92 | HCRTR1 (0.46) | CYP2C9CYP2C19HCRTR1HCRTR2UBE2M | |
| SCHEMBL14959024 | 0.92 | HCRTR1 (0.46) | CYP2C9CYP2C19HCRTR1HCRTR2UBE2M | |
| SCHEMBL24016934 | 0.92 | HCRTR1 (0.46) | CYP2C9CYP2C19HCRTR1HCRTR2UBE2M | |
| SCHEMBL25132815 | 0.92 | HCRTR1 (0.46) | CYP2C9CYP2C19HCRTR1HCRTR2UBE2M | |
| SCHEMBL18609695 | 0.91 | HSD17B10 (0.46) | CYP2C9UBE2MDCUN1D1TSHRNPSR1 | |
| SCHEMBL24016857 | 0.91 | HSD17B10 (0.46) | CYP2C9UBE2MDCUN1D1TSHRNPSR1 | |
| SCHEMBL14959019 | 0.91 | HSD17B10 (0.46) | CYP2C9UBE2MDCUN1D1TSHRNPSR1 | |
| SCHEMBL12176222 | 0.88 | HSD17B10 (0.43) | CYP2C9HCRTR1HCRTR2UBE2MDCUN1D1 | |
| SCHEMBL12176101 | 0.88 | RXFP1 (0.43) | CYP2C9UBE2MDCUN1D1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-3078658-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2381778-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
| US-20150141425-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8906938-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141425-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CYP2C9 2859/4885CYP2C19 2355/4885HCRTR1 154/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CYP2C9 2859/4885CYP2C19 2355/4885HCRTR1 154/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CYP2C9 2859/4885CYP2C19 2355/4885HCRTR1 154/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CYP2C9 2859/4885CYP2C19 2355/4885HCRTR1 154/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CYP2C9 2859/4885CYP2C19 2355/4885HCRTR1 154/4885 |
| US-20170065604-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CYP2C9 2216/4885CYP2C19 1812/4885HCRTR1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.